HALO
$63.43+0.16 (+0.25%)
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
Recent News
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and r
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness
Halozyme Therapeutics (NasdaqGS:HALO) has appointed David Ramsay as Interim Chief Financial Officer. Ramsay, a former finance leader at the company with extensive biotechnology experience, will oversee financial operations during the search for a permanent CFO. The leadership change comes at a time when the company continues to manage growth initiatives and capital allocation priorities. For investors watching Halozyme Therapeutics, the CFO transition lands against a mixed share price...
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 1.3% and t
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback
If you are wondering whether Halozyme Therapeutics at around US$69.40 is still attractively priced or starting to look expensive, you are in the right place. The share price closed at US$69.40, with returns of a 1.4% decline over 7 days, a 3.2% decline over 30 days, a 1.3% decline year to date, but 19.4% over 1 year, 59.9% over 3 years and 65.8% over 5 years, which can shape how the market is currently weighing its risks and opportunities. Recent attention on Halozyme has been influenced by...